SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardano is drawing intense community focus as traders debate whether current price levels represent a generational accumulation opportunity or a signal of deeper long-term decline. While some market participants are aggressively buying the dip in anticipation of future upgrades and regulatory catalysts, others remain deeply skeptical, citing ongoing project stagnation and the lack of immediate institutional adoption.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors actively anticipate the upcoming Phase 3 IZAR-1 trial results, with community speculation centered on whether this data will serve as a definitive catalyst for a potential buyout. Shareholders are closely tracking potential announcement timelines following management's previous guidance, while debating the impact of ongoing institutional short interest and recent insider trading activity on the stock's near-term price performance.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is seeing heightened community discourse as investors debate its long-term potential following recent partnerships and infrastructure updates, despite significant downward price pressure and frustration over recent volatility. Many participants remain focused on the project's institutional narrative, viewing the current market dip as an accumulation opportunity while expressing impatience for official confirmation on key milestones like the planned bank acquisition.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is seeing significant investor attention as the market awaits critical Phase 3 clinical trial data for its mental health programs, with the community actively debating the company's valuation, cash runway, and long-term commercialization strategy relative to its peers. Traders are closely monitoring the sector for regulatory updates and upcoming trial results, reflecting high conviction in the potential of next-generation psychiatric therapeutics.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is experiencing significant volatility as investors debate its valuation relative to its underlying holdings, such as Anthropic, OpenAI, and SpaceX. While some market participants are aggressively buying in anticipation of future private company IPOs, others warn that the fund is currently trading at a substantial premium to its net asset value, urging caution ahead of upcoming share lockup expirations.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing heightened market activity and community debate, driven by a combination of positive catalysts like gas-free stablecoin transfers and aggressive speculation regarding potential short squeezes. Investors are actively discussing the token's recovery potential and institutional staking trends, while maintaining a polarized outlook on whether the current momentum marks a sustainable breakout or a temporary relief rally.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is rallying significantly as investors respond to a new partnership with AI firm Midjourney to utilize ultrasound-on-chip technology for a novel full-body scanning platform. While bulls are energized by the potential for expanded licensing revenue and long-term tech disruption, the community remains polarized with skeptics pointing toward persistent cash burn, high insider selling, and concerns about potential future equity dilution.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors debate management's silence and the lack of traditional earnings calls, with speculation swirling that CEO Kevin Tang's activist-style leadership and aggressive insider share accumulation are setting the stage for a potential M&A event. Community sentiment is sharply divided between frustrated retail long-term holders seeking transparency and those interpreting the low-volume volatility and lack of public communication as strategic posturing during private buyout negotiations.

Investment Managers Series Trust II - Tradr 2X Long SNDK Daily ETF

Tradr 2X Long SNDK Daily ETF

SNXX is experiencing significant volatility driven by the intense price action of its underlying asset, SNDK, as traders capitalize on memory sector momentum. The community is actively debating the risks of this leveraged product, focusing on the impact of corporate actions like share splits and the dangers of overnight decay during rapid market swings.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is experiencing significant volatility and heavy trading volume as investors debate the impact of a major bridge security breach versus the project's long-term potential as a privacy-focused layer. The community remains deeply divided, with some actively accumulating during the price correction while others express frustration over the ongoing supply pressure and the project's ability to maintain its narrative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PANW Sentinel One(S) is growing revenues at a similar rate as Palo Alto (PANW), but has a better balance sheet, better technology and a better valuation (P/S ratio) than PANW, as seen below:  
  
               R. Growth      Debt       P/S     Technology  
PANW     20-23%         $2B         23         ho-hum  
S               20-23%            0            6           excellent  
 
S   vs   PANW (Technology) 
https://www.sentinelone.com/vs/palo-alto-networks/ 
 
Final thought: If Sentinel One (S) just traded at the SAME... P/S ratio as PANW(23), Sentinel One&#39;s stock price would be approximately $72/sh 
 
Is the above why Sentinel One&#39;s Put/Call ratio is extremely bullish ?  Yes, along with merger interest from Cisco Systems. 
https://www.barchart.com/stocks/quotes/S/put-call-ratios

StockTwits Web

Palo Alto Networks Inc

 Sentinel One(S) is growing revenues at a similar rate as Palo Alto (PANW), but has a better balance sheet, better technology and a better valuation (P/S ratio) than PANW, as seen below:  
  
               R. Growth      Debt       P/S     Technology  
PANW     20-23%         $2B         23         ho-hum  
S               20-23%            0            6           excellent  
 
S   vs   PANW (Technology) 


 
 
Final thought: If Sentinel One (S) just traded at the SAME... P/S ratio as PANW(23), Sentinel One's stock price would be approximately $72/sh 
 
Is the above why Sentinel One's Put/Call ratio is extremely bullish ?  Yes, along with merger interest from Cisco Systems. 
